Rhythm Biosciences Limited (ASX: RHY) has confirmed that antibodies for the final two adjunct biomarkers for the ColoSTAT test have been successfully technically validated, stabilised and proven to be reproduceable.
Rhythm’s ColoSTAT test-kit, is expected to be a global, low-cost, simple blood test for the detection of colorectal cancer aimed at mass market screening.
Rhythm CEO, Glenn Gilbert, said that all five technically validated biomarkers (one lead, four adjunct) are intended to be combined in a single test that will form the final ColoSTAT test-kit.
Mr Gilbert said the completion of the technical validation of all current biomarkers is a critical milestone achievement and provides increased confidence as the development programme progresses on the path towards commercialisation.
With the core antibody technology technically validated, Mr Gilbert said the company is focusing on completing the next phase in the development programme which includes refining the ColoSTAT test-kit algorithm, via further analytical cancerous and healthy blood sample testing, transferring the core technology to a third party (high volume) manufacturer and completing further verification testing to finalise the first prototype test-kit.
It is a very exciting time for the company. We are buoyed with the significant progress we have made with the core technology,” Mr Gilbert said.
A considerable amount of work has gone into selecting, screening, optimising and now technically validating the antibodies for the biomarkers that we expect will make up the final ColoSTAT test-kit.”
